GHRS

GH Research PLC

Healthcare
Biotechnology
$1.86B market cap

Forecast run · Sep 14, 2026Upside rank 705 of 3,136

Model Signal

ForecastQ Daily Probabilities

51.1%

43.7%

27.3%

Analyst Consensus

Recommendation2.00/5 Buy

Last price$27.20

Price target$48.83

Implied move+79.5%

Analysts9

ForecastQ Portfolios

GHRS is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.

Company Profile

GH Research PLC is a clinical-stage biopharmaceutical firm dedicated to creating novel therapies for psychiatric and neurological conditions. The company primarily concentrates on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) treatments, specifically targeting patients with treatment-resistant depression (TRD). Its most advanced program is GH001, an inhalable 5-MeO-DMT product candidate that has successfully completed two Phase 1 clinical trials and a subsequent Phase 1/2 clinical trial in TRD patients. Additionally, GH Research is developing GH002, an injectable 5-MeO-DMT candidate, and GH003, an intranasal 5-MeO-DMT candidate. Both GH002 and GH003 are currently in preclinical development, with a focus on their potential applications in various psychiatric and neurological disorders. Founded in 2018, GH Research PLC is headquartered in Dublin, Ireland.